Seretide at all doses and devices is indicated in the regular treatment of asthma for patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting β2 agonist or patients already adequately controlled on both inhaled corticosteroid and long-acting β2 agonist.
The Seretide 50/500mg Diskus is also licensed for regular use in COPD for patients with a FEV1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy. For further indication details please refer to the SPC
Over 102.49 million patient treatment years and counting1
Three strengths in two different devices: metered dose inhaler (MDI) and dry powder inhaler (DPI)2
Studied in over 90 clinical trials3